866-997-4948(US-Canada Toll Free)

Europe Urological Cancer Drugs Market Report 2017

Published By :

QYResearch

Published Date : Feb 2017

Category :

Cancer

No. of Pages : 122 Pages

Notes:
Sales, means the sales volume of Urological Cancer Drugs
Revenue, means the sales value of Urological Cancer Drugs

This report studies sales (consumption) of Urological Cancer Drugs in Europe market, especially in Germany, France, UK, Russia, Italy, Spain and Benelux, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A.
Tolmar Inc

Market Segment by Countries, this report splits Europe into several key Countries, with sales (consumption), revenue, market share and growth rate of Urological Cancer Drugs in these countries, from 2011 to 2021 (forecast), like
Germany
France
UK
Russia
Italy
Spain
Benelux

Split by product type, with sales, revenue, price, market share and growth rate of each type, can be divided into
Xofigo (Radium Ra 223 Dichloride)
Jevtana (Cabazitaxel)
Inlyta (Axitinib)
Votrient (Pazopanib Hydrochloride)
Sutent (Sunitinib Malate)
Zytiga (Abiraterone Acetate)
Xtandi (Enzalutamide)
Opdivo (Nivolumab)
Provenge (Sipuleucel-T)

Split by application, this report focuses on sales, market share and growth rate of Urological Cancer Drugs in each application, can be divided into
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular Cancer

Table of Contents

Europe Urological Cancer Drugs Market Report 2017
1 Urological Cancer Drugs Overview
1.1 Product Overview and Scope of Urological Cancer Drugs
1.2 Classification of Urological Cancer Drugs
1.2.1 Xofigo (Radium Ra 223 Dichloride)
1.2.2 Jevtana (Cabazitaxel)
1.2.3 Inlyta (Axitinib)
1.2.4 Votrient (Pazopanib Hydrochloride)
1.2.5 Sutent (Sunitinib Malate)
1.2.6 Zytiga (Abiraterone Acetate)
1.2.7 Xtandi (Enzalutamide)
1.2.8 Opdivo (Nivolumab)
1.2.9 Provenge (Sipuleucel-T)
1.3 Application of Urological Cancer Drugs
1.3.1 Prostate Cancer
1.3.2 Bladder Cancer
1.3.3 Kidney Cancer
1.3.4 Testicular Cancer
1.4 Urological Cancer Drugs Market by Countries
1.4.1 Germany Status and Prospect (2012-2022)
1.4.2 France Status and Prospect (2012-2022)
1.4.3 UK Status and Prospect (2012-2022)
1.4.4 Russia Status and Prospect (2012-2022)
1.4.5 Italy Status and Prospect (2012-2022)
1.4.6 Spain Status and Prospect (2012-2022)
1.4.7 Benelux Status and Prospect (2012-2022)
1.5 Europe Market Size (Value and Volume) of Urological Cancer Drugs (2012-2022)
1.5.1 Europe Urological Cancer Drugs Sales and Growth Rate (2012-2022)
1.5.2 Europe Urological Cancer Drugs Revenue and Growth Rate (2012-2022)

2 Europe Urological Cancer Drugs by Manufacturers, Type and Application
2.1 Europe Urological Cancer Drugs Market Competition by Manufacturers
2.1.1 Europe Urological Cancer Drugs Sales and Market Share of Key Manufacturers (2015 and 2016)
2.1.2 Europe Urological Cancer Drugs Revenue and Share by Manufacturers (2015 and 2016)
2.2 Europe Urological Cancer Drugs (Volume and Value) by Type
2.2.1 Europe Urological Cancer Drugs Sales and Market Share by Type (2012-2017)
2.2.2 Europe Urological Cancer Drugs Revenue and Market Share by Type (2012-2017)
2.3 Europe Urological Cancer Drugs (Volume and Value) by Countries
2.3.1 Europe Urological Cancer Drugs Sales and Market Share by Countries (2012-2017)
2.3.2 Europe Urological Cancer Drugs Revenue and Market Share by Countries (2012-2017)
2.4 Europe Urological Cancer Drugs (Volume) by Application

3 Germany Urological Cancer Drugs (Volume, Value and Sales Price)
3.1 Germany Urological Cancer Drugs Sales and Value (2012-2017)
3.1.1 Germany Urological Cancer Drugs Sales and Growth Rate (2012-2017)
3.1.2 Germany Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
3.1.3 Germany Urological Cancer Drugs Sales Price Trend (2012-2017)
3.2 Germany Urological Cancer Drugs Sales and Market Share by Manufacturers
3.3 Germany Urological Cancer Drugs Sales and Market Share by Type
3.4 Germany Urological Cancer Drugs Sales and Market Share by Application

4 France Urological Cancer Drugs (Volume, Value and Sales Price)
4.1 France Urological Cancer Drugs Sales and Value (2012-2017)
4.1.1 France Urological Cancer Drugs Sales and Growth Rate (2012-2017)
4.1.2 France Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
4.1.4 France Urological Cancer Drugs Sales Price Trend (2012-2017)
4.2 France Urological Cancer Drugs Sales and Market Share by Manufacturers
4.3 France Urological Cancer Drugs Sales and Market Share by Type
4.4 France Urological Cancer Drugs Sales and Market Share by Application

5 UK Urological Cancer Drugs (Volume, Value and Sales Price)
5.1 UK Urological Cancer Drugs Sales and Value (2012-2017)
5.1.1 UK Urological Cancer Drugs Sales and Growth Rate (2012-2017)
5.1.2 UK Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
5.1.5 UK Urological Cancer Drugs Sales Price Trend (2012-2017)
5.2 UK Urological Cancer Drugs Sales and Market Share by Manufacturers
5.3 UK Urological Cancer Drugs Sales and Market Share by Type
5.4 UK Urological Cancer Drugs Sales and Market Share by Application

6 Russia Urological Cancer Drugs (Volume, Value and Sales Price)
6.1 Russia Urological Cancer Drugs Sales and Value (2012-2017)
6.1.1 Russia Urological Cancer Drugs Sales and Growth Rate (2012-2017)
6.1.2 Russia Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
6.1.6 Russia Urological Cancer Drugs Sales Price Trend (2012-2017)
6.2 Russia Urological Cancer Drugs Sales and Market Share by Manufacturers
6.3 Russia Urological Cancer Drugs Sales and Market Share by Type
6.4 Russia Urological Cancer Drugs Sales and Market Share by Application

7 Italy Urological Cancer Drugs (Volume, Value and Sales Price)
7.1 Italy Urological Cancer Drugs Sales and Value (2012-2017)
7.1.1 Italy Urological Cancer Drugs Sales and Growth Rate (2012-2017)
7.1.2 Italy Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
7.1.7 Italy Urological Cancer Drugs Sales Price Trend (2012-2017)
7.2 Italy Urological Cancer Drugs Sales and Market Share by Manufacturers
7.3 Italy Urological Cancer Drugs Sales and Market Share by Type
7.4 Italy Urological Cancer Drugs Sales and Market Share by Application

8 Spain Urological Cancer Drugs (Volume, Value and Sales Price)
8.1 Spain Urological Cancer Drugs Sales and Value (2012-2017)
8.1.1 Spain Urological Cancer Drugs Sales and Growth Rate (2012-2017)
8.1.2 Spain Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
8.1.8 Spain Urological Cancer Drugs Sales Price Trend (2012-2017)
8.2 Spain Urological Cancer Drugs Sales and Market Share by Manufacturers
8.3 Spain Urological Cancer Drugs Sales and Market Share by Type
8.4 Spain Urological Cancer Drugs Sales and Market Share by Application

9 Benelux Urological Cancer Drugs (Volume, Value and Sales Price)
9.1 Benelux Urological Cancer Drugs Sales and Value (2012-2017)
9.1.1 Benelux Urological Cancer Drugs Sales and Growth Rate (2012-2017)
9.1.2 Benelux Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
9.1.9 Benelux Urological Cancer Drugs Sales Price Trend (2012-2017)
9.2 Benelux Urological Cancer Drugs Sales and Market Share by Manufacturers
9.3 Benelux Urological Cancer Drugs Sales and Market Share by Type
9.4 Benelux Urological Cancer Drugs Sales and Market Share by Application

10 Europe Urological Cancer Drugs Manufacturers Analysis
10.1 Novartis
10.1.1 Company Basic Information, Manufacturing Base and Competitors
10.1.2 Urological Cancer Drugs Product Type, Application and Specification
10.1.2.1 Xofigo (Radium Ra 223 Dichloride)
10.1.2.2 Jevtana (Cabazitaxel)
10.1.3 Novartis Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
10.1.4 Main Business/Business Overview
10.2 Pfizer
10.2.1 Company Basic Information, Manufacturing Base and Competitors
10.2.2 Urological Cancer Drugs Product Type, Application and Specification
10.2.2.1 Xofigo (Radium Ra 223 Dichloride)
10.2.2.2 Jevtana (Cabazitaxel)
10.2.3 Pfizer Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
10.2.4 Main Business/Business Overview
10.3 Johnson & Johnson
10.3.1 Company Basic Information, Manufacturing Base and Competitors
10.3.2 Urological Cancer Drugs Product Type, Application and Specification
10.3.2.1 Xofigo (Radium Ra 223 Dichloride)
10.3.2.2 Jevtana (Cabazitaxel)
10.3.3 Johnson & Johnson Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
10.3.4 Main Business/Business Overview
10.4 AstraZeneca
10.4.1 Company Basic Information, Manufacturing Base and Competitors
10.4.2 Urological Cancer Drugs Product Type, Application and Specification
10.4.2.1 Xofigo (Radium Ra 223 Dichloride)
10.4.2.2 Jevtana (Cabazitaxel)
10.4.3 AstraZeneca Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
10.4.4 Main Business/Business Overview
10.5 Astellas
10.5.1 Company Basic Information, Manufacturing Base and Competitors
10.5.2 Urological Cancer Drugs Product Type, Application and Specification
10.5.2.1 Xofigo (Radium Ra 223 Dichloride)
10.5.2.2 Jevtana (Cabazitaxel)
10.5.3 Astellas Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
10.5.4 Main Business/Business Overview
10.6 Bristol-Myers Squibb
10.6.1 Company Basic Information, Manufacturing Base and Competitors
10.6.2 Urological Cancer Drugs Product Type, Application and Specification
10.6.2.1 Xofigo (Radium Ra 223 Dichloride)
10.6.2.2 Jevtana (Cabazitaxel)
10.6.3 Bristol-Myers Squibb Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
10.6.4 Main Business/Business Overview
10.7 Abbott Laboratories
10.7.1 Company Basic Information, Manufacturing Base and Competitors
10.7.2 Urological Cancer Drugs Product Type, Application and Specification
10.7.2.1 Xofigo (Radium Ra 223 Dichloride)
10.7.2.2 Jevtana (Cabazitaxel)
10.7.3 Abbott Laboratories Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
10.7.4 Main Business/Business Overview
10.8 Celgene Corporation
10.8.1 Company Basic Information, Manufacturing Base and Competitors
10.8.2 Urological Cancer Drugs Product Type, Application and Specification
10.8.2.1 Xofigo (Radium Ra 223 Dichloride)
10.8.2.2 Jevtana (Cabazitaxel)
10.8.3 Celgene Corporation Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
10.8.4 Main Business/Business Overview
10.9 Dendreon Corporation
10.9.1 Company Basic Information, Manufacturing Base and Competitors
10.9.2 Urological Cancer Drugs Product Type, Application and Specification
10.9.2.1 Xofigo (Radium Ra 223 Dichloride)
10.9.2.2 Jevtana (Cabazitaxel)
10.9.3 Dendreon Corporation Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
10.9.4 Main Business/Business Overview
10.10 Ferring Pharmaceuticals
10.10.1 Company Basic Information, Manufacturing Base and Competitors
10.10.2 Urological Cancer Drugs Product Type, Application and Specification
10.10.2.1 Xofigo (Radium Ra 223 Dichloride)
10.10.2.2 Jevtana (Cabazitaxel)
10.10.3 Ferring Pharmaceuticals Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
10.10.4 Main Business/Business Overview
10.11 GlaxoSmithKline
10.12 Indevus Pharmaceuticals Inc
10.13 Ipsen
10.14 Roche Healthcare
10.15 Sanofi S.A.
10.16 Tolmar Inc

11 Urological Cancer Drugs Manufacturing Cost Analysis
11.1 Urological Cancer Drugs Key Raw Materials Analysis
11.1.1 Key Raw Materials
11.1.2 Price Trend of Key Raw Materials
11.1.3 Key Suppliers of Raw Materials
11.1.4 Market Concentration Rate of Raw Materials
11.2 Proportion of Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Manufacturing Process Analysis of Urological Cancer Drugs

12 Industrial Chain, Sourcing Strategy and Downstream Buyers
12.1 Urological Cancer Drugs Industrial Chain Analysis
12.2 Upstream Raw Materials Sourcing
12.3 Raw Materials Sources of Urological Cancer Drugs Major Manufacturers in 2015
12.4 Downstream Buyers

13 Marketing Strategy Analysis, Distributors/Traders
13.1 Marketing Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Development Trend
13.2 Market Positioning
13.2.1 Pricing Strategy
13.2.2 Brand Strategy
13.2.3 Target Client
13.3 Distributors/Traders List

14 Europe Urological Cancer Drugs Market Forecast (2017-2022)
14.1 Germany Urological Cancer Drugs Sales Forecast (2017-2022)
14.2 France Urological Cancer Drugs Sales Forecast (2017-2022)
14.3 UK Urological Cancer Drugs Sales Forecast (2017-2022)
14.4 Russia Urological Cancer Drugs Sales Forecast (2017-2022)
14.5 Italy Urological Cancer Drugs Sales Forecast (2017-2022)
14.6 Spain Urological Cancer Drugs Sales Forecast (2017-2022)
14.7 Benelux Urological Cancer Drugs Sales Forecast (2017-2022)
14.8 Europe Urological Cancer Drugs Sales Forecast by Type (2017-2022)
14.9 Europe Urological Cancer Drugs Sales Forecast by Application (2017-2022)

15 Research Findings and Conclusion

16 Appendix
Methodology
Analyst Introduction
Data Source


List of Table

List of Tables and Figures

Figure Picture of Urological Cancer Drugs
Table Classification of Urological Cancer Drugs
Figure Europe Sales Market Share of Urological Cancer Drugs by Type in 2015
Figure Xofigo (Radium Ra 223 Dichloride) Picture
Figure Jevtana (Cabazitaxel) Picture
Figure Inlyta (Axitinib) Picture
Figure Votrient (Pazopanib Hydrochloride) Picture
Figure Sutent (Sunitinib Malate) Picture
Figure Zytiga (Abiraterone Acetate) Picture
Figure Xtandi (Enzalutamide) Picture
Figure Opdivo (Nivolumab) Picture
Figure Provenge (Sipuleucel-T) Picture
Table Application of Urological Cancer Drugs
Figure Europe Sales Market Share of Urological Cancer Drugs by Application in 2015
Figure Prostate Cancer Examples
Figure Bladder Cancer Examples
Figure Kidney Cancer Examples
Figure Testicular Cancer Examples
Figure Germany Urological Cancer Drugs Revenue and Growth Rate (2012-2022)
Figure France Urological Cancer Drugs Revenue and Growth Rate (2012-2022)
Figure UK Urological Cancer Drugs Revenue and Growth Rate (2012-2022)
Figure Russia Urological Cancer Drugs Revenue and Growth Rate (2012-2022)
Figure Italy Urological Cancer Drugs Revenue and Growth Rate (2012-2022)
Figure Spain Urological Cancer Drugs Revenue and Growth Rate (2012-2022)
Figure Benelux Urological Cancer Drugs Revenue and Growth Rate (2012-2022)
Figure Europe Urological Cancer Drugs Sales and Growth Rate (2012-2022)
Figure Europe Urological Cancer Drugs Revenue and Growth Rate (2012-2022)
Table Europe Urological Cancer Drugs Sales of Key Manufacturers (2015 and 2016)
Table Europe Urological Cancer Drugs Sales Share by Manufacturers (2015 and 2016)
Figure 2015 Urological Cancer Drugs Sales Share by Manufacturers
Figure 2016 Urological Cancer Drugs Sales Share by Manufacturers
Table Europe Urological Cancer Drugs Revenue by Manufacturers (2015 and 2016)
Table Europe Urological Cancer Drugs Revenue Share by Manufacturers (2015 and 2016)
Table 2015 Europe Urological Cancer Drugs Revenue Share by Manufacturers
Table 2016 Europe Urological Cancer Drugs Revenue Share by Manufacturers
Table Europe Urological Cancer Drugs Sales and Market Share by Type (2012-2017)
Table Europe Urological Cancer Drugs Sales Share by Type (2012-2017)
Figure Sales Market Share of Urological Cancer Drugs by Type (2012-2017)
Figure Europe Urological Cancer Drugs Sales Growth Rate by Type (2012-2017)
Table Europe Urological Cancer Drugs Revenue and Market Share by Type (2012-2017)
Table Europe Urological Cancer Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Urological Cancer Drugs by Type (2012-2017)
Figure Europe Urological Cancer Drugs Revenue Growth Rate by Type (2012-2017)
Table Europe Urological Cancer Drugs Sales and Market Share by Countries (2012-2017)
Table Europe Urological Cancer Drugs Sales Share by Countries (2012-2017)
Figure Sales Market Share of Urological Cancer Drugs by Countries (2012-2017)
Table Europe Urological Cancer Drugs Revenue and Market Share by Countries (2012-2017)
Table Europe Urological Cancer Drugs Revenue Share by Countries (2012-2017)
Figure Revenue Market Share of Urological Cancer Drugs by Countries (2012-2017)
Table Europe Urological Cancer Drugs Sales and Market Share by Application (2012-2017)
Table Europe Urological Cancer Drugs Sales Share by Application (2012-2017)
Figure Sales Market Share of Urological Cancer Drugs by Application (2012-2017)
Figure Germany Urological Cancer Drugs Sales and Growth Rate (2012-2017)
Figure Germany Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
Figure Germany Urological Cancer Drugs Sales Price Trend (2012-2017)
Table Germany Urological Cancer Drugs Sales by Manufacturers (2015 and 2016)
Table Germany Urological Cancer Drugs Market Share by Manufacturers (2015 and 2016)
Table Germany Urological Cancer Drugs Sales by Type (2015 and 2016)
Table Germany Urological Cancer Drugs Market Share by Type (2015 and 2016)
Table Germany Urological Cancer Drugs Sales by Application (2015 and 2016)
Table Germany Urological Cancer Drugs Market Share by Application (2015 and 2016)
Figure France Urological Cancer Drugs Sales and Growth Rate (2012-2017)
Figure France Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
Figure France Urological Cancer Drugs Sales Price Trend (2012-2017)
Table France Urological Cancer Drugs Sales by Manufacturers (2015 and 2016)
Table France Urological Cancer Drugs Market Share by Manufacturers (2015 and 2016)
Table France Urological Cancer Drugs Sales by Type (2015 and 2016)
Table France Urological Cancer Drugs Market Share by Type (2015 and 2016)
Table France Urological Cancer Drugs Sales by Application (2015 and 2016)
Table France Urological Cancer Drugs Market Share by Application (2015 and 2016)
Figure UK Urological Cancer Drugs Sales and Growth Rate (2012-2017)
Figure UK Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
Figure UK Urological Cancer Drugs Sales Price Trend (2012-2017)
Table UK Urological Cancer Drugs Sales by Manufacturers (2015 and 2016)
Table UK Urological Cancer Drugs Market Share by Manufacturers (2015 and 2016)
Table UK Urological Cancer Drugs Sales by Type (2015 and 2016)
Table UK Urological Cancer Drugs Market Share by Type (2015 and 2016)
Table UK Urological Cancer Drugs Sales by Application (2015 and 2016)
Table UK Urological Cancer Drugs Market Share by Application (2015 and 2016)
Figure Russia Urological Cancer Drugs Sales and Growth Rate (2012-2017)
Figure Russia Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
Figure Russia Urological Cancer Drugs Sales Price Trend (2012-2017)
Table Russia Urological Cancer Drugs Sales by Manufacturers (2015 and 2016)
Table Russia Urological Cancer Drugs Market Share by Manufacturers (2015 and 2016)
Table Russia Urological Cancer Drugs Sales by Type (2015 and 2016)
Table Russia Urological Cancer Drugs Market Share by Type (2015 and 2016)
Table Russia Urological Cancer Drugs Sales by Application (2015 and 2016)
Table Russia Urological Cancer Drugs Market Share by Application (2015 and 2016)
Figure Italy Urological Cancer Drugs Sales and Growth Rate (2012-2017)
Figure Italy Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
Figure Italy Urological Cancer Drugs Sales Price Trend (2012-2017)
Table Italy Urological Cancer Drugs Sales by Manufacturers (2015 and 2016)
Table Italy Urological Cancer Drugs Market Share by Manufacturers (2015 and 2016)
Table Italy Urological Cancer Drugs Sales by Type (2015 and 2016)
Table Italy Urological Cancer Drugs Market Share by Type (2015 and 2016)
Table Italy Urological Cancer Drugs Sales by Application (2015 and 2016)
Table Italy Urological Cancer Drugs Market Share by Application (2015 and 2016)
Figure Spain Urological Cancer Drugs Sales and Growth Rate (2012-2017)
Figure Spain Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
Figure Spain Urological Cancer Drugs Sales Price Trend (2012-2017)
Table Spain Urological Cancer Drugs Sales by Manufacturers (2015 and 2016)
Table Spain Urological Cancer Drugs Market Share by Manufacturers (2015 and 2016)
Table Spain Urological Cancer Drugs Sales by Type (2015 and 2016)
Table Spain Urological Cancer Drugs Market Share by Type (2015 and 2016)
Table Spain Urological Cancer Drugs Sales by Application (2015 and 2016)
Table Spain Urological Cancer Drugs Market Share by Application (2015 and 2016)
Figure Benelux Urological Cancer Drugs Sales and Growth Rate (2012-2017)
Figure Benelux Urological Cancer Drugs Revenue and Growth Rate (2012-2017)
Figure Benelux Urological Cancer Drugs Sales Price Trend (2012-2017)
Table Benelux Urological Cancer Drugs Sales by Manufacturers (2015 and 2016)
Table Benelux Urological Cancer Drugs Market Share by Manufacturers (2015 and 2016)
Table Benelux Urological Cancer Drugs Sales by Type (2015 and 2016)
Table Benelux Urological Cancer Drugs Market Share by Type (2015 and 2016)
Table Benelux Urological Cancer Drugs Sales by Application (2015 and 2016)
Table Benelux Urological Cancer Drugs Market Share by Application (2015 and 2016)
Table Urological Cancer Drugs Basic Information List
Table Novartis Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Figure Novartis Urological Cancer Drugs Sales Market Share (2012-2017)
Table Pfizer Basic Information List
Table Pfizer Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table Pfizer Urological Cancer Drugs Sales Market Share (2012-2017)
Table Johnson & Johnson Basic Information List
Table Johnson & Johnson Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table Johnson & Johnson Urological Cancer Drugs Sales Market Share (2012-2017)
Table AstraZeneca Basic Information List
Table AstraZeneca Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table AstraZeneca Urological Cancer Drugs Sales Market Share (2012-2017)
Table Astellas Basic Information List
Table Astellas Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table Astellas Urological Cancer Drugs Sales Market Share (2012-2017)
Table Bristol-Myers Squibb Basic Information List
Table Bristol-Myers Squibb Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table Bristol-Myers Squibb Urological Cancer Drugs Sales Market Share (2012-2017)
Table Abbott Laboratories Basic Information List
Table Abbott Laboratories Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table Abbott Laboratories Urological Cancer Drugs Sales Market Share (2012-2017)
Table Celgene Corporation Basic Information List
Table Celgene Corporation Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table Celgene Corporation Urological Cancer Drugs Sales Market Share (2012-2017)
Table Dendreon Corporation Basic Information List
Table Dendreon Corporation Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table Dendreon Corporation Urological Cancer Drugs Sales Market Share (2012-2017)
Table Ferring Pharmaceuticals Basic Information List
Table Ferring Pharmaceuticals Urological Cancer Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table Ferring Pharmaceuticals Urological Cancer Drugs Sales Market Share (2012-2017)
Table GlaxoSmithKline Basic Information List
Table Indevus Pharmaceuticals Inc Basic Information List
Table Ipsen Basic Information List
Table Roche Healthcare Basic Information List
Table Sanofi S.A. Basic Information List
Table Tolmar Inc Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Urological Cancer Drugs
Figure Manufacturing Process Analysis of Urological Cancer Drugs
Figure Urological Cancer Drugs Industrial Chain Analysis
Table Raw Materials Sources of Urological Cancer Drugs Major Manufacturers in 2015
Table Major Buyers of Urological Cancer Drugs
Table Distributors/Traders List
Figure Germany Urological Cancer Drugs Sales and Growth Rate Forecast (2017-2022)
Figure Germany Urological Cancer Drugs Revenue and Growth Rate Forecast (2017-2022)
Figure France Urological Cancer Drugs Sales and Growth Rate Forecast (2017-2022)
Figure France Urological Cancer Drugs Revenue and Growth Rate Forecast (2017-2022)
Figure UK Urological Cancer Drugs Sales and Growth Rate Forecast (2017-2022)
Figure UK Urological Cancer Drugs Revenue and Growth Rate Forecast (2017-2022)
Figure Russia Urological Cancer Drugs Sales and Growth Rate Forecast (2017-2022)
Figure Russia Urological Cancer Drugs Revenue and Growth Rate Forecast (2017-2022)
Figure Italy Urological Cancer Drugs Sales and Growth Rate Forecast (2017-2022)
Figure Italy Urological Cancer Drugs Revenue and Growth Rate Forecast (2017-2022)
Figure Spain Urological Cancer Drugs Sales and Growth Rate Forecast (2017-2022)
Figure Spain Urological Cancer Drugs Revenue and Growth Rate Forecast (2017-2022)
Figure Benelux Urological Cancer Drugs Sales and Growth Rate Forecast (2017-2022)
Figure Benelux Urological Cancer Drugs Revenue and Growth Rate Forecast (2017-2022)
Table Europe Urological Cancer Drugs Sales Forecast by Type (2017-2022)
Table Europe Urological Cancer Drugs Sales Forecast by Application (2017-2022)

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *